Heron Therapeutics Inc Revenue Growth Rates (HRTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Heron Therapeutics Inc   (NASDAQ: HRTX)
 

HRTX's Revenue Growth by Quarter and Year

Heron Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HRTX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 37.67
1st Quarter March 34.07
FY 71.74

HRTXs Annual Revenue
Heron Therapeutics Inc 's Revenue in the fiscal year 2025 $ 154.56 millions
Heron Therapeutics Inc 's Revenue in the fiscal year 2024 $ 143.64 millions
Heron Therapeutics Inc 's Revenue in the fiscal year 2023 $ 126.94 millions
Heron Therapeutics Inc 's Revenue in the fiscal year 2022 $ 107.67 millions
Heron Therapeutics Inc 's Revenue in the fiscal year 2021 $ 86.35 millions




HRTX Revenue second quarter 2026 Y/Y Growth Comment
Heron Therapeutics Inc reported Revenue growth of 3.65% year on year in the second quarter 2026, to $ 37.67 millions, this is lower than Heron Therapeutics Inc 's recent average Revenue improvement of 24.46%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Revenue growth. While Heron Therapeutics Inc ' s Revenue increase of 3.65% ranks overall at the positon no. 2412 in the second quarter 2026.


HRTX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 2.21 % 21 % 14.35 %
3rd Quarter September - 15.3 % 3.59 % 17.58 %
2nd Quarter June 3.65 % 2.34 % 11.81 % 14.95 %
1st Quarter March -11.39 % 12.33 % 15.56 % 26.26 %
FY   - 7.6 % 13.15 % -

Financial Statements
Heron Therapeutics Inc 's second quarter 2026 Revenue $ 37.67 millions HRTX's Income Statement
Heron Therapeutics Inc 's second quarter 2025 Revenue $ 36.34 millions Quarterly HRTX's Income Statement


HRTX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 13.86 % 28.44 % 9.96 %
3rd Quarter September - 2.64 % -8.9 % -1.67 %
2nd Quarter June 10.55 % -5.49 % 3.74 % 7.22 %
1st Quarter March -19.78 % -7.46 % -0.32 % -1.37 %
FY (Year on Year)   - 7.6 % 13.15 % -


Back to HRTX Growth rate Comparisons >> Back to HRTX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #354
Overall #2412

Revenue Y/Y Growth Statistics
High Average Low
168.92 % 24.46 % -40.43 %
(Dec 31 2018)   (Mar 31 2021)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #354
Overall #2412
Revenue Y/Y Growth Statistics
High Average Low
168.92 % 24.46 % -40.43 %
(Dec 31 2018)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Heron Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
183.97 % 15.18 % -37.69 %
(Mar 31 2017)  


HRTX's II. Quarter Q/Q Revenue Comment
Heron Therapeutics Inc achieved in the II. Quarter 2026 below company average Revenue rise of 10.55% quarter on quarter, to $ 37.67 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -5.49% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 50 other companies have achieved higher Revenue quarter on quarter growth. While Heron Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 783.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #51
Healthcare Sector #123
Overall #783
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #51
Healthcare Sector #123
Overall #783
Revenue Q/Q Growth Statistics
High Average Low
183.97 % 15.18 % -37.69 %
(Mar 31 2017)  


HRTX's II. Quarter Q/Q Revenue Comment
Heron Therapeutics Inc achieved in the II. Quarter 2026 below company average Revenue rise of 10.55% quarter on quarter, to $ 37.67 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -5.49% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 50 other companies have achieved higher Revenue quarter on quarter growth. While Heron Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 783.


Heron Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 151.51 $ 150.18 $ 154.56 $ 153.64 $ 148.69
Y / Y Revenue Growth (TTM) 1.89 % 1.57 % 7.6 % 12.62 % 9.9 %
Year on Year Revenue Growth Overall Ranking # 1405 # 1022 # 590 # 1067 # 508
Seqeuential Revenue Change (TTM) 0.88 % -2.83 % 0.6 % 3.33 % 0.57 %
Seq. Revenue Growth (TTM) Overall Ranking # 2412 # 1884 # 1111 # 999 # 1272


Cumulative Revenue growth Comment
Although Heron Therapeutics Inc 's Annual Revenue growth year on year were below company's average 24.46% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1.89% year on year, from 1.57% in Mar 31 2026.

In the Healthcare sector 241 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1022 to 1405.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 117
Healthcare Sector # 242
Overall # 1405

Revenue TTM Y/Y Growth Statistics
High Average Low
168.92 %
 24.46 %
-40.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 117
Sector # 354
S&P 500 # 2412
Cumulative Revenue growth Comment
Although Heron Therapeutics Inc 's Annual Revenue growth year on year were below company's average 24.46% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1.89% year on year, from 1.57% in Mar 31 2026.

In the Healthcare sector 241 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1022 to 1405.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 117
Healthcare Sector # 242
Overall # 1405

Revenue TTM Y/Y Growth Statistics
High Average Low
168.92 %
24.46 %
-40.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 117
Sector # 354
S&P 500 # 2412




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HRTX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Msa Safety Inc6.25%$ 6.252 millions
Pacira Biosciences inc 6.24%$ 6.240 millions
Globus Medical Inc 5.94%$ 5.940 millions
Labcorp Holdings Inc 5.78%$ 5.778 millions
Tandem Diabetes Care Inc 5.77%$ 5.768 millions
Bristol myers Squibb Company5.74%$ 5.738 millions
Haemonetics Corporation5.65%$ 5.646 millions
Progyny Inc 5.58%$ 5.584 millions
Cytek Biosciences Inc 5.57%$ 5.566 millions
Amphastar Pharmaceuticals Inc 5.44%$ 5.441 millions
Becton Dickinson And Company5.44%$ 5.438 millions
Bruker Corporation5.22%$ 5.220 millions
Davita Inc 5.17%$ 5.165 millions
Park Dental Partners Inc 5.10%$ 5.102 millions
Lumexa Imaging Holdings Inc 5.08%$ 5.076 millions
Merck and Co Inc 5.07%$ 5.068 millions
Cv Sciences Inc 4.96%$ 4.958 millions
Viatris Inc 4.88%$ 4.877 millions
Fulgent Genetics Inc 4.86%$ 4.855 millions
Zimmer Biomet Holdings Inc 4.80%$ 4.799 millions
Mettler toledo International Inc 4.48%$ 4.485 millions
Phibro Animal Health Corporation4.40%$ 4.405 millions
Align Technology inc 4.35%$ 4.355 millions
Opko Health Inc 4.32%$ 4.319 millions
Dariohealth Corp 4.29%$ 4.291 millions
Orthofix Medical Inc 4.15%$ 4.147 millions
Pediatrix Medical Group Inc 4.04%$ 4.040 millions
Nrc Health3.98%$ 3.978 millions
Bioventus Inc 3.76%$ 3.757 millions
Heron Therapeutics Inc 3.64%$ 3.640 millions


About Heron Therapeutics Inc Revenue Growth Rates (HRTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Heron Therapeutics Inc (CIK 818033).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-341301
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Heron Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.